Twist Bioscience Corp (NASDAQ:TWST) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 3,210,000 shares, an increase of 12.2% from the September 30th total of 2,860,000 shares. Based on an average trading volume of 220,200 shares, the days-to-cover ratio is currently 14.6 days. Approximately 17.6% of the company’s stock are short sold.
NASDAQ:TWST opened at $21.86 on Friday. The company’s 50 day moving average is $23.31 and its two-hundred day moving average is $26.69. The company has a market cap of $699.53 million and a PE ratio of -0.86. The company has a current ratio of 7.18, a quick ratio of 6.96 and a debt-to-equity ratio of 0.03. Twist Bioscience has a twelve month low of $13.99 and a twelve month high of $35.95.
Several research firms have weighed in on TWST. Zacks Investment Research downgraded shares of Twist Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, October 5th. ValuEngine raised shares of Twist Bioscience from a “hold” rating to a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Twist Bioscience presently has an average rating of “Buy” and an average price target of $26.55.
In related news, CFO James M. Thorburn sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $29.81, for a total transaction of $298,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patrick Weiss sold 14,730 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $30.66, for a total transaction of $451,621.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 281,143 shares of company stock valued at $7,532,938. 29.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of TWST. BlackRock Inc. raised its position in shares of Twist Bioscience by 320.7% in the second quarter. BlackRock Inc. now owns 1,532,141 shares of the company’s stock valued at $44,447,000 after buying an additional 1,167,949 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Twist Bioscience by 90.2% in the second quarter. JPMorgan Chase & Co. now owns 1,997,857 shares of the company’s stock valued at $56,220,000 after buying an additional 947,399 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Twist Bioscience by 321.8% in the second quarter. Vanguard Group Inc. now owns 1,055,474 shares of the company’s stock valued at $30,619,000 after purchasing an additional 805,251 shares during the period. Emerald Advisers LLC grew its holdings in shares of Twist Bioscience by 146.5% in the second quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock valued at $16,814,000 after purchasing an additional 344,463 shares during the period. Finally, Emerald Mutual Fund Advisers Trust grew its holdings in shares of Twist Bioscience by 156.0% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock valued at $15,204,000 after purchasing an additional 319,373 shares during the period. Institutional investors and hedge funds own 42.69% of the company’s stock.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Further Reading: What is a good rate of return for a mutual fund?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.